HUE049278T2 - Pirazolok - Google Patents
PirazolokInfo
- Publication number
- HUE049278T2 HUE049278T2 HUE15775837A HUE15775837A HUE049278T2 HU E049278 T2 HUE049278 T2 HU E049278T2 HU E15775837 A HUE15775837 A HU E15775837A HU E15775837 A HUE15775837 A HU E15775837A HU E049278 T2 HUE049278 T2 HU E049278T2
- Authority
- HU
- Hungary
- Prior art keywords
- pyrazoles
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/02—Halogenated hydrocarbons
- A61K31/025—Halogenated hydrocarbons carbocyclic
- A61K31/03—Halogenated hydrocarbons carbocyclic aromatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Psychology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Addiction (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Communicable Diseases (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462037815P | 2014-08-15 | 2014-08-15 | |
| US201562146629P | 2015-04-13 | 2015-04-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE049278T2 true HUE049278T2 (hu) | 2020-09-28 |
Family
ID=54261065
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE15775837A HUE049278T2 (hu) | 2014-08-15 | 2015-08-14 | Pirazolok |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | USRE49517E1 (enExample) |
| EP (1) | EP3180315B1 (enExample) |
| JP (1) | JP6618525B2 (enExample) |
| DK (1) | DK3180315T3 (enExample) |
| ES (1) | ES2791252T3 (enExample) |
| HU (1) | HUE049278T2 (enExample) |
| PL (1) | PL3180315T3 (enExample) |
| PT (1) | PT3180315T (enExample) |
| WO (1) | WO2016025918A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2791186T3 (es) | 2014-08-15 | 2020-11-03 | Janssen Pharmaceuticals Inc | Triazoles como inhibidores de receptores NR2B |
| SMT202000134T1 (it) | 2015-07-09 | 2020-05-08 | Janssen Pharmaceutica Nv | 4-azaindoli sostituiti e loro uso come modulatori del recettore glun2b |
| KR20180108822A (ko) | 2016-02-10 | 2018-10-04 | 얀센 파마슈티카 엔.브이. | Nr2b-선택적 nmda 조절제로서 치환된 1,2,3-트라이아졸 |
| US10487055B2 (en) | 2016-06-01 | 2019-11-26 | Rhode Island Board Of Education | Diindole compounds useful in treatment of nervous system disorders |
| TW201819376A (zh) | 2016-10-06 | 2018-06-01 | 比利時商健生藥品公司 | 經取代之1H-咪唑並[4,5-b]吡啶-2(3H)-酮及其作為GLUN2B受體調節劑之用途 |
| MA52244A (fr) * | 2018-04-04 | 2021-02-17 | Janssen Pharmaceutica Nv | Pyridine et pyrimidines substituées et leur utilisation en tant que modulateurs du récepteur glun2b |
| MX2021015506A (es) | 2019-06-14 | 2022-02-10 | Janssen Pharmaceutica Nv | Amidas de pirazolo-piridina sustituidas y su uso como moduladores del receptor glun2b. |
| JP7667097B2 (ja) | 2019-06-14 | 2025-04-22 | ヤンセン ファーマシューティカ エヌ.ベー. | 置換ピラゾロ-ピリジンアミド及びglun2b受容体調節因子としてのその使用 |
| EP3983072A1 (en) | 2019-06-14 | 2022-04-20 | Janssen Pharmaceutica NV | Pyrazine carbamates and their use as glun2b receptor modulators |
| BR112021025136A2 (pt) | 2019-06-14 | 2022-01-25 | Janssen Pharmaceutica Nv | Pirazolo[4,3-b]piridinas substituídas e seu uso como moduladoras do receptor de glun2b |
| MX2021015508A (es) | 2019-06-14 | 2022-01-31 | Janssen Pharmaceutica Nv | Carbamatos de piridina y su uso como moduladores del receptor glun2b. |
| US11993587B2 (en) | 2019-06-14 | 2024-05-28 | Janssen Pharmaceutica Nv | Substituted pyrazolo-pyrazines and their use as GluN2B receptor modulators |
| PE20220806A1 (es) | 2019-06-14 | 2022-05-20 | Janssen Pharmaceutica Nv | Pirazolo piridinas heteroaromaticas sustituidas y su uso como moduladores del receptor glun2b |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6610723B2 (en) * | 2001-01-29 | 2003-08-26 | Hoffmann-La Roche Inc. | Imidazole derivatives |
| AU2003214412A1 (en) | 2002-03-28 | 2003-10-13 | Eisai R & D Management Co., Ltd. | 7-azaindoles as inhibitors of c-jun n-terminal kinases for the treatment of neurodegenerative disorders |
| JP2007523178A (ja) | 2004-02-18 | 2007-08-16 | アストラゼネカ アクチボラグ | 代謝型グルタメート受容体アンタゴニストとしてのトリアゾール化合物およびそれらの使用 |
| EP1963268B1 (en) | 2005-12-07 | 2010-12-01 | NSAB, Filial af NeuroSearch Sweden AB, Sverige | Disubstituted phenylpiperidines as modulators of cortical catecholaminergic neurotransmission |
| US7807704B2 (en) | 2006-03-30 | 2010-10-05 | Chemocentryx, Inc. | Bicyclic, nitrogen-containing compounds modulating CXCR4 and/or CCXCKR2 |
| PE20090717A1 (es) | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | Derivados de quinolina como inhibidores de la pi3 quinasa |
| NZ581127A (en) * | 2007-05-25 | 2012-06-29 | Abbott Gmbh & Co Kg | Heterocyclic compounds as positive modulators of metabotropic glutamate receptor 2 (mglu2 receptor) |
| US20100227846A1 (en) * | 2007-08-30 | 2010-09-09 | Takeda Pharmaceutical Company Limited | Substituted pyrazole derivative |
| WO2009058261A1 (en) | 2007-10-31 | 2009-05-07 | Merck & Co., Inc. | Modulation of sleep with nr2b receptor antagonists |
| MX2010009649A (es) | 2008-03-27 | 2010-12-17 | Evotecv Neurosciences Gmbh | Metodos para tratar trastornos utilizando un antagonista selectivo del subtipo nr2b de nmda. |
| JP5411927B2 (ja) | 2008-05-06 | 2014-02-12 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ccr1アンタゴニストとしてのピラゾール化合物 |
| NZ590688A (en) | 2008-08-05 | 2012-09-28 | Daiichi Sankyo Co Ltd | imidazo[4,5-b]pyridin-2-one derivatives |
| US8697689B2 (en) | 2008-10-16 | 2014-04-15 | Janssen Pharmaceuticals, Inc. | Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors |
| CN102264743B (zh) | 2008-11-25 | 2015-02-11 | 罗彻斯特大学 | Mlk抑制剂及其使用方法 |
| KR20130094710A (ko) | 2010-04-14 | 2013-08-26 | 어레이 바이오파마 인크. | Jak 키나아제의 억제제로서 5,7-치환된-이미다조[1,2-c]피리미딘 |
| US9434743B2 (en) * | 2012-03-02 | 2016-09-06 | Takeda Pharmaceutical Company Limited | Indazole derivatives |
| WO2014124651A1 (en) | 2013-02-15 | 2014-08-21 | Københavns Universitet | Pyrrolidine-2-carboxylic acid derivatives as iglur antagonists |
| JP2016516710A (ja) | 2013-03-13 | 2016-06-09 | アッヴィ・インコーポレイテッド | ピリジン系cdk9キナーゼ阻害薬 |
| ES2791186T3 (es) | 2014-08-15 | 2020-11-03 | Janssen Pharmaceuticals Inc | Triazoles como inhibidores de receptores NR2B |
| SMT202000134T1 (it) | 2015-07-09 | 2020-05-08 | Janssen Pharmaceutica Nv | 4-azaindoli sostituiti e loro uso come modulatori del recettore glun2b |
| KR20180108822A (ko) | 2016-02-10 | 2018-10-04 | 얀센 파마슈티카 엔.브이. | Nr2b-선택적 nmda 조절제로서 치환된 1,2,3-트라이아졸 |
| TW201819376A (zh) | 2016-10-06 | 2018-06-01 | 比利時商健生藥品公司 | 經取代之1H-咪唑並[4,5-b]吡啶-2(3H)-酮及其作為GLUN2B受體調節劑之用途 |
-
2015
- 2015-08-14 US US17/124,879 patent/USRE49517E1/en active Active
- 2015-08-14 PL PL15775837T patent/PL3180315T3/pl unknown
- 2015-08-14 ES ES15775837T patent/ES2791252T3/es active Active
- 2015-08-14 EP EP15775837.6A patent/EP3180315B1/en active Active
- 2015-08-14 US US15/503,875 patent/US10155727B2/en not_active Ceased
- 2015-08-14 WO PCT/US2015/045413 patent/WO2016025918A1/en not_active Ceased
- 2015-08-14 DK DK15775837.6T patent/DK3180315T3/da active
- 2015-08-14 PT PT157758376T patent/PT3180315T/pt unknown
- 2015-08-14 HU HUE15775837A patent/HUE049278T2/hu unknown
- 2015-08-14 JP JP2017508553A patent/JP6618525B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3180315A1 (en) | 2017-06-21 |
| JP6618525B2 (ja) | 2019-12-11 |
| WO2016025918A1 (en) | 2016-02-18 |
| DK3180315T3 (da) | 2020-04-06 |
| EP3180315B1 (en) | 2020-03-18 |
| JP2017525700A (ja) | 2017-09-07 |
| US10155727B2 (en) | 2018-12-18 |
| US20170275254A1 (en) | 2017-09-28 |
| PL3180315T3 (pl) | 2020-09-07 |
| ES2791252T3 (es) | 2020-11-03 |
| USRE49517E1 (en) | 2023-05-02 |
| PT3180315T (pt) | 2020-05-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3237446T3 (en) | Anti-PD-1-antistoffer | |
| DK3236972T3 (en) | Antivirale N4-hydroxycytidin-derivativer | |
| DK3373003T3 (en) | Urinteststrimmel | |
| AU361515S (en) | Dishrack | |
| AU362944S (en) | Lapboard | |
| PL3180315T3 (pl) | Pirazole | |
| IL250306A0 (en) | indazoles | |
| DK3191586T3 (en) | Cellobiosephosphorylase | |
| DK3178931T3 (en) | Anti-orai1-antistof | |
| DK3002465T3 (en) | Hydrauliksystem | |
| DK3194944T3 (en) | Tomografiapparat | |
| GB201401268D0 (en) | TrackPack | |
| DK3145380T3 (en) | Toiletventilationssystem | |
| DK3234061T3 (en) | Nano-inhibitorer | |
| AU5594P (en) | Lanoregon Mandevilla sanderi | |
| AU5593P (en) | Lanmissouri Mandevilla sanderi | |
| AU5598P (en) | Lanidaho Mandevilla sanderi | |
| AU5585P (en) | Lanutah Mandevilla sanderi | |
| AU5584P (en) | Laniowa Mandevilla sanderi | |
| AU5597P (en) | Lancalifornia Mandevilla sanderi | |
| AU5583P (en) | Lanminnesota Mandevilla sanderi | |
| AU5591P (en) | Lanmontana Mandevilla sanderi | |
| AU5596P (en) | Lannevada Mandevilla sanderi | |
| AU5285P (en) | FLOMANRER Mandevilla sanderi | |
| AU5286P (en) | FLOMANWHW Mandevilla sanderi |